PulmonologyNews.net

Pulmonology Xagena

Search results for "Glycopyrronium"

QVA149 ( Ultibro Breezhaler ) is an inhaled fixed-dose combination therapy under development for the treatment of chronic obstructive pulmonary disease ( COPD ). It combines Indacaterol (a long acting ...


Researchers have evaluated the effect of dual, long acting inhaled bronchodilator treatment on exacerbations in patients with severe and very severe chronic obstructive pulmonary disease ( COPD ).In t ...


Chronic obstructive pulmonary disease ( COPD ) is characterized by persistent airflow limitation caused by bronchial alterations, small airways disease and parenchymal destruction. In patients with CO ...


Two once-daily long-acting muscarinic antagonists ( LAMAs ) are currently available for the treatment of chronic obstructive pulmonary disease ( COPD ), Tiotropium ( Spiriva ) and Glycopyrronium ( See ...


Glycopyrronium bromide ( NVA237; Seebri Breezhaler ) is a once-daily long-acting muscarinic antagonist ( LAMA ) in development for chronic obstructive pulmonary disease ( COPD ). The GLOW2 ( GLyco ...


Glycopyrronium ( Seebri Breezhaler ) is a once daily long-acting muscarinic antagonist that is approved for maintenance treatment of COPD ( chronic obstructive pulmonary disease ). This post-hoc poole ...


Inhaled Glycopyrronium bromide ( Seebri Breezhaler; NVA237 ) is a once-daily, long-acting muscarinic receptor antagonist ( LAMA ) that is approved in several countries, as a maintenance bronchodilator ...


COPD exacerbations are linked to a rapid decline in lung function and increased mortality. QVA149 ( Ultibro Breezhaler ) is a once-daily dual bronchodilator with a fixed-dose combination of long-actin ...


QVA149 ( Ultibro Breezhaler ), a novel, once-daily dual bronchodilator containing the long-acting beta2-agonist, Indacaterol and long-acting muscarinic antagonist Glycopyrronium, improves lung functio ...


Dual bronchodilation with a long-acting beta2-agonist ( LABA ) and long-acting muscarinic antagonist ( LAMA ) is recommended for patients with a high symptomatic burden and/or risk of exacerbations ( ...


Chronic obstructive pulmonary disease ( COPD ) is frequently accompanied by multimorbidities in affected patients. Even though the majority of these comorbidities are also related to advanced age and ...